Longeveron Secures U.S. Patent for Stem Cell Treatment of Aging-Related Frailty
Key Insights
Longeveron received U.S. Patent No. 12,465,620 covering methods of treating aging-related frailty (search) with inflammaging (search) using mesenchymal stem cells (search), providing patent protection through 2038.
The patent addresses an unmet medical need as no approved treatments currently exist for aging-related frailty (search), a syndrome characterized by weakness, low physical activity, and exhaustion.
Laromestrocel, the company's lead mesenchymal stem cell therapy, has demonstrated positive initial results in Phase 1 and 2 clinical trials for aging-related frailty (search).
Longeveron Inc. (NASDAQ: LGVN) announced that the United States Patent and Trademark Office has granted the biotechnology company a patent covering the administration of its proprietary mesenchymal stem cells (search) for treating patients with aging-related frailty (search) symptoms. The patent, numbered 12,465,620 and entitled "Method of Treating Aging Frailty in Subjects with Inflammaging (search) Using Human Mesenchymal Stem Cells," provides Longeveron with patent rights in the United States through 2038, with potential for further patent term extensions alongside regulatory exclusivity extensions.
Addressing an Unmet Medical Need
Aging-related frailty (search) represents a significant clinical challenge, as no approved treatments currently exist for this syndrome affecting older individuals. The condition is characterized by weakness, low physical activity, slowed motor performance, exhaustion, and unintentional weight loss. According to the company, aging-related frailty is a syndrome of multisystem physiological dysregulation occurring in older individuals which diminishes human healthspan.
The patent specifically relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (search) to patients with aging-related frailty (search) accompanied by inflammaging (search). Many studies demonstrate a direct correlation between aging-related frailty and inflammation, with inflammaging receiving considerable attention for proposing a link between immune changes and numerous diseases and conditions common in old age.
Clinical Development Progress
Longeveron has previously conducted Phase 1 and 2 studies in aging-related frailty (search) designed to show improvements in the six-minute walk test and physical functioning for its lead MSC drug, laromestrocel. The company reports that laromestrocel has delivered positive initial results across two clinical trials in aging-related frailty.
Laromestrocel Mechanism and Applications
Laromestrocel (Lomecel-B®) is a living cell product made from specialized cells isolated from the bone marrow of young healthy adult donors. These mesenchymal signaling cells (search) are essential to the body's endogenous biological repair mechanism and have been shown to perform complex functions including new tissue formation. The cells respond to sites of injury or disease and secrete bioactive factors that are immunomodulatory and regenerative.
According to Longeveron, laromestrocel MSCs may have multiple potential mechanisms of action that could lead to anti-inflammatory, pro-vascular regenerative responses, potentially providing broad application for a range of rare and aging-related diseases. The therapy encompasses pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects.
Broader Pipeline Development
Beyond aging-related frailty (search), Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (search) (HLHS), Alzheimer's disease (search), and Pediatric Dilated Cardiomyopathy (search) (DCM). The laromestrocel development programs have received five distinct FDA designations, including Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation for the HLHS program, and Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the Alzheimer's disease program.